Peptide Comparison
IGF-1 DES vs MGF
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.
Data-derived verdict
IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than MGF (Preclinical + Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| IGF-1 DES | MGF | |
|---|---|---|
| Class | IGF-1 analog (truncated); anabolic | IGF-1 splice variant peptide; anabolic |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity | Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage |
| Route | SC / IM | IM (localized) |
| Half-life | ~30 min | ~5-7 min |
| Dosage (research) | 50-150 mcg SC near target muscle | 100-400 mcg post-workout IM into target muscle |
| Evidence tier | Anecdotal + Animal Studies | Preclinical + Anecdotal |
| Research depth | 25 indexed | 68 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Hypoglycemia; localized tissue growth; theoretical cancer risk | Very short half-life; injection site only; limited human data |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick IGF-1 DES or MGF?
IGF-1 DES has stronger documented evidence (Anecdotal + Animal Studies) than MGF (Preclinical + Anecdotal) while both occupy the igf-1 class. When clinical-evidence tier is the deciding factor, IGF-1 DES is the safer pick. MGF may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between IGF-1 DES and MGF?
IGF-1 DES is classed as IGF-1 analog (truncated); anabolic; MGF is classed as IGF-1 splice variant peptide; anabolic. Reported mechanism: IGF-1 DES, Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity; MGF, Local muscle IGF-1 splice variant; activates satellite cells after mechanical damage. Reported half-life: IGF-1 DES, ~30 min; MGF, ~5-7 min. Routes in published studies: IGF-1 DES, SC / IM; MGF, IM (localized).
Which has stronger evidence, IGF-1 DES or MGF?
IGF-1 DES has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 DES is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 25 indexed studies. MGF is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 68 indexed studies.
Which is more accessible, IGF-1 DES or MGF?
Neither IGF-1 DES nor MGF is an FDA-approved drug. Catalog status: IGF-1 DES, Research Chemical; MGF, Research Chemical.
Are IGF-1 DES and MGF ever combined?
IGF-1 DES and MGF appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…